<DOC>
	<DOCNO>NCT00379613</DOCNO>
	<brief_summary>The purpose study determine optimal dose sugammadex compound administer deep neuromuscular block . Sugammadex administer shortly ( 5 minute ) administration high dose ( 1.2 mg/kg ) neuromuscular block agent rocuronium . Under circumstance neuromuscular block deep . The safety pharmacokinetics sugammadex also study .</brief_summary>
	<brief_title>Use Sugammadex Administered 5 Minutes After Administration 1.2 mg/kg EsmeronÂ® ( 19.4.205 ) ( P05942 )</brief_title>
	<detailed_description />
	<mesh_term>Rocuronium</mesh_term>
	<criteria>ASA 1 2 age 18 64 , inclusive Scheduled surgical procedure anticipate duration anesthesia least 90 minute , without need muscle relaxation intubation Scheduled surgery supine position Given write informed consent Subjects difficult intubation anatomical malformation expect Subjects know suspected neuromuscular disorder impair neuromuscular block ( NMB ) and/or significant renal dysfunction Subjects know suspect ( family ) history malignant hyperthermia Subjects know suspect allergy narcotic , muscle relaxant medication use general anesthesia Subjects receive medication know interfere neuromuscular block agent anticonvulsant Mg2+ Subjects already participate CT 19.4.205 Subjects participate another clinical trial , preapproved NV Organon , within 30 day enter CT 19.4.205 Female subject pregnant : female pregnancy exclude medical history hCG test within 24 hour surgery except female childbearing potential i.e . least 2 year postmenopausal underwent tubal ligation hysterectomy Females childbearing potential use acceptable method birth control : condom diaphragm spermicide , vasectomized partner ( &gt; 6 month ) , IUD , abstinence Subjects give breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>